Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C26H28Cl2N4O5 |
| Molecular Weight | 547.43 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)N1CCN(CC1)C2=CC=C(OC[C@H]3CO[C@@](CN4C=NC(O)=C4)(O3)C5=C(Cl)C=C(Cl)C=C5)C=C2
InChI
InChIKey=VOCPLEFXUSVSRD-NVQXNPDNSA-N
InChI=1S/C26H28Cl2N4O5/c1-18(33)31-8-10-32(11-9-31)20-3-5-21(6-4-20)35-14-22-15-36-26(37-22,16-30-13-25(34)29-17-30)23-7-2-19(27)12-24(23)28/h2-7,12-13,17,22,34H,8-11,14-16H2,1H3/t22-,26-/m0/s1
| Molecular Formula | C26H28Cl2N4O5 |
| Molecular Weight | 547.43 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 13:48:28 GMT 2023
by
admin
on
Sat Dec 16 13:48:28 GMT 2023
|
| Record UNII |
A5BAG8KDK5
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
156613660
Created by
admin on Sat Dec 16 13:48:28 GMT 2023 , Edited by admin on Sat Dec 16 13:48:28 GMT 2023
|
PRIMARY | |||
|
A5BAG8KDK5
Created by
admin on Sat Dec 16 13:48:28 GMT 2023 , Edited by admin on Sat Dec 16 13:48:28 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> METABOLITE INACTIVE |
Evidence that CYP3A4 plays a significant role in metabolism of ketoconazole is that coadministration of CYP3A4 inducers, such as phenytoin, carbamazepine, and rifampin, can cause as much as a 50%reduction in levels of ketoconazole.
MAY BE CLINICALLY SIGNIFICANT
|
